Table 1 Clinicopathological features of 58 cases of original LCNEC

1. [10]

Ia

11/left

None

LSO/ROVBx/OM/AP/PALA/peritoneal Bx

TC

NED10 m

2. [11]

Ia

14/right

None

TAH/BSO/OM

BEP

NED 9 m

3. [12]

IV

9/left

None

TAH/BSO/OM/nephrectomy/resection of brain metastasis

TC → γ -knife

NED 12 m

4. [6]

IV

11/right

None

BSO/TAH/OM/peritoneal Bx

TC (neo adjuvant)

NED 64 m

5. [13]

IIIc

15/left, 7/right

None

BSO/OM//PALA/bladder and sigmoid colon deposit excision

EP

NED 6 m

6. [14]

IV

25/left

None

BSO/TAH/partialOM/AP

TC

DOD 3 m

7. [15]

IIIc

6/left

None

TAH/BSO

No

AWD 3 m

8. [16]

IIIc

9/right

None

TAH/BSO/OM

Yes

DOD 22 m

9. [17]

IIb

35/eft

None

TAH/BSO/OM

No

DOD post op

10. [18]

IV

15/unclear

None

Palliative surgery

Etoposide&carboplatin

DOD 1.5 m

11. [18]

Ia

Unclear/left

None

TAH/BSO/LM/OM

TP → taxotere

DOD 17 m

12. [18]

III

13/left

None

TAH/BSO/LM/OM/PALA/peritoneal Bx

TC

NED 5 m

13. [19]

IV

13/right

None

TAH/BSO/LM/OM/PALA/peritoneal Bx

Etoposide&carboplatin →TC

NED 36 m

14. [20]

III

12/right

None

TAH/BSO/OM

No

DOD 4 m

15 present case

IIIc

20/right

None

TAH/BSO/OM

EP

NED 3 m

16. [21]

IIIb

6.5/right

Serous carcinoma

TAH/BSO

TC

NED 8 m

17. [22]

Ic

11/unclear

Serous adenocarcinoma & malignant brenner tumor

TAH/BSO/LM/OM/AP/PALA

TP

NED 24 m

18. [23]

IIIc

7/right, 5/left

Serous adenocarcinoma with focal mucin secretion

BSO/OM

TC → Doxil

DOD 7 m

19. [24]

Ia

25/left

Mucinous intraepithelial adenocarcinoma

TAH/BSO/OM

TC

DOD 4 m

20. [2]

Ib

18/right

Mucinous cystadenoma (BLM) & partial intraepithelial carcinoma

TAH/BSO/OM

Yes

DOD 36 m

21. [2]

IIIb

30/left

Mucinous cystadenoma (BLM) & partial intraepithelial carcinoma

TAH/BSO/OM/AP/LM/peritoneal Bx

Yes

DOD 8 m

22. [25]

Ic

16/left

Mucinous cystadenoma (BLM) & mucinous adenocarcinoma

TAH/BSO/OM

CP

DOD 8 m

23. [3]

I

21/right

Mucinous tumor (BLM) & mucinous adenocarcinoma

RSO/AP

CP

DOD 3 m

24. [4]

Ia

21/right

Mucinous cystadenoma (BLM) & mucinous adenocarcinoma

RSO/AP

CP

DOD 3 m

25. [3]

I

26/right

Mucinous tumor (BLM) & intraepithelial carcinoma

TAH/BSO

Pt-based chemotherapy

NED 68 m

26. [3]

III

13.5/right

Mucinous tumor (BLM)

TAH/BSO

Pt-based chemotherapy

DOD 2 m

27. [26]

IV

10/unclear

Mucinous tumor (BLM)

TAH/BSO/OM/LM/PALA /prior oophorocystectomy

TC

DOD7m

28. [3]

I

14/right

Mucinous & endometrioid carcinoma

TAH/BSO

Pt-based chemotherapy

NED 66 m

29. [9]

Ia

15/right

Mucinous adenoma

TAH/BSO/LM/OM

EP → TC

DOD 7 m

30. [27]

Ia

16.5/left

Mucinous adenoma

TAH/BSO/LM/OM/AP

No

DOD10m

31. [28]

Ic

Unclear

Mucinous adenoma

TAH/BSO/OM

Pt-based chemotherapy

NED 120m

32. [29]

IV

20/left

Adenocarcinoma

TAH/BSO/LM/OM

Etoposide&carboplatin, palliative radiation therapy

DOD 7 m

33. [3]

IV

5/right

Mucinous adenocarcinoma

TAH/BSO

Pt-based chemotherapy

AWD 8 m

34. [24]

IIIc

11/left

Mucinous micro invasive adenocarcinoma

BSO/OM/LM(Bx)/prior TAH

TP 

DOD 8 m

35. [3]

I

14/ left

Adenocarcinoma, NOS

BSO

Pt-based chemotherapy

NED 28 m

36. [30]

III

15/right

Mucinous cystadenoma (BLM) & mucinous adenocarcinoma

TAH/BSO/OM/AP

Yes

DOD 4 m

37. [31]

Ia

30/left

Mucinous adenoma, cystadenoma (BLM) & mucinous adenocarcinoma

TAH/BSO/LM/OM/AP/PALA

Yes

NED 8 m

38. [32]

Ia

5/right

Mucinous tumor (BLM)

RSO

BEP → TC

DOD 5 m

39. [33]

Ia

16/right, unclear/left

Mucinous tumor (BLM)

TAH/BSO/LM/OM/AP

No

NED 6 m

40. [34]

I

15/right

Mucinous cystadenoma (BLM) & mucinous adenoma

TAH/BSO/LM/OM

No

NED 3 m

41. [35]

IIIc

26/right

Mucinous endocervical tumor (BLM)& intraepithelial carcinoma

TAH/BSO/LM/OM

Yes

NED 6 m

42. [6]

Ic

15/left

Endometrioid adenocarcinoma & squamous differentiation mucinous adenocarcinoma

TAH/BSO/OM

TC

DOD 2 m

43. [6]

IIc

7/left

Endometrioid adenocarcinoma

TAH/BSO/PLA/OM/AP

TC

NED 40 m

44. [6]

IIIb

13/left,

unclear/right

Endometrioid adenocarcinoma

TAH/BSO/PLA/OM/PALA

TC

NED 32 m

45. [2]

Ia

15/unclear

Endometrioid adenocarcinoma

TAH/BSO/LM/peritoneal Bx

No

DOD 19 m

46. [36]

Ic

11/left

Endometrioid adenocarcinoma

LSO/ROVBx/partial OM

Camptosar

DOD 6 m

47. [3]

III

14.5/left

Endometrioid adenocarcinoma

TAH/BSO

Pt-based chemotherapy

NED 37 m

48. [3]

IV

14/left

Endometrioid adenocarcinoma

TAH/RSO

Pt-based chemotherapy

DOD 9 m

49. [37]

III

4.6/left

Endometrioid adenocarcinoma

TAH/BSO/LM/OM/peritoneal Bx

Yes

NED 4 m

50. [38]

I

21/left

Mucinous tumor (BLM), invasive mucinous adenocarcinoma & teratoma

TAH/BSO/LM/OM

EP

DOD 7 m

51. [38]

IV

20/left

Mucinous tumor (BLM), invasive mucinous adenocarcinoma & teratoma

TAH/BSO/LM/OM/peritoneal Bx

TC

DOD 5 m

52. [3]

III

14/right

Adenocarcinoma, teratoma & NOS

TAH/BSO

Pt-based chemotherapy

NED 11 m

53. [28]

IIc

18/right

Mucinous carcinoma & teratoma

TAH/BSO/peritoneal Bx/PLA

No

DOD 10 m

54. [16]

Ic

18/right

Mucinous adenocarcinoma & teratoma

TAH/BSO/LM

No

DOD 10 m

55. [3]

IV

5/right

Teratoma

BSO/OM/AP

Pt-based chemotherapy

DOD 36 m

56. [39]

IV

15/left

Teratoma

LSO/thoracic Bx

TC

DOD 6 m

57. [39].

III

Unclear

Teratoma

TAH/BSO/ sigmoid resection

Yes

NED 12 m

58. [3]

IV

Unclear

Benign cyst & teratoma (contralateral ovary)

TAH/BSO

Pt-based chemotherapy

DOD 20 m